首页 > 最新文献

Przegla̜d Gastroenterologiczny最新文献

英文 中文
Intrahepatic aneurysm in a branch of the right hepatic artery in a patient with vasculitis due to systemic lupus erythematosus. 一名系统性红斑狼疮血管炎患者的右肝动脉分支肝内动脉瘤。
IF 1.7 Q3 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-01-01 Epub Date: 2024-03-14 DOI: 10.5114/pg.2024.136247
Zoi Nitsa, Francesk Mulita, Maria Sotiropoulou, Andreas Panagakis, Markos Despotidis, Lysandros Karydakis, Dimitrios Schizas, Michail Vailas
{"title":"Intrahepatic aneurysm in a branch of the right hepatic artery in a patient with vasculitis due to systemic lupus erythematosus.","authors":"Zoi Nitsa, Francesk Mulita, Maria Sotiropoulou, Andreas Panagakis, Markos Despotidis, Lysandros Karydakis, Dimitrios Schizas, Michail Vailas","doi":"10.5114/pg.2024.136247","DOIUrl":"https://doi.org/10.5114/pg.2024.136247","url":null,"abstract":"","PeriodicalId":20719,"journal":{"name":"Przegla̜d Gastroenterologiczny","volume":"19 2","pages":"214-216"},"PeriodicalIF":1.7,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11200073/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141470338","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Safety and efficacy of Single-Pass Albumin Dialysis (SPAD), Prometheus, and Molecular Adsorbent Recycling System (MARS) liver haemodialysis vs. Standard Medical Therapy (SMT): meta-analysis and systematic review. 单程白蛋白透析(SPAD)、普罗米修斯(Prometheus)和分子吸附剂循环系统(MARS)肝脏血液透析与标准医疗疗法(SMT)的安全性和有效性:荟萃分析和系统综述。
IF 1.7 Q3 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-01-01 Epub Date: 2024-04-29 DOI: 10.5114/pg.2024.139297
Eyad Gadour, Mohammed Abdullah Kaballo, Khalid Shrwani, Zeinab Hassan, Ahmed Kotb, Ahmed Aljuraysan, Bogdan Miuţescu, Nouf Sherwani, Waleed Mahallawi

Introduction: Because not all liver dysfunction patients are suitable for transplantations and there is a shortage of grafts, liver support therapies have gained interest. In this regard, extracorporeal albumin dialysis devices such as single-pass albumin dialysis (SPAD), Prometheus, and molecular adsorbent recycling system (MARS) have been valuable in supplementing standard medical therapy (SMT). However, the efficacy and safety of these devices is often questioned.Aim: We performed a systematic review to summarize the efficacy and safety of MARS, SPAD, and Prometheus as supportive treatments for liver dysfunction.

Material and methods: PubMed, Medline, Cochrane Library, Web of Science, and Google Scholar electronic databases were extensively searched for all randomized trials published in English. In addition, meta-analytic analyses were performed with Review Manager software, and Cochrane's risk of bias tool embedded in this software was used for bias assessment.

Results: Twelve trials including a total of 653 patients were eligible for inclusion. Subgroup analyses of data from these trials revealed that MARS and Prometheus were associated with significant removal of bilirubin (MD = -5.14 mg/dl; 95% CI: -7.26 - -3.02; p < 0.00001 and MD = -8.11 mg/dl; 95% CI: -12.40 - -3.82; p = 0.0002, respectively) but not bile acids and ammonia when compared to SMT. Furthermore, MARS was as effective as Prometheus and SPAD in the reduction of bilirubin (MD = 2.98 mg/dl; 95% CI: -4.26 - 10.22; p = 0.42 and MD = 0.67 mg/dl; 95% CI: -2.22 - 3.56; p = 0.65), bile acids (MD = -17.06 µmol/l; 95% CI: -64.33 - 30.20; p = 0.48 and MD = 16.21 µmol/l; 95% CI: -17.26 - 49.68; p = 0.34), and ammonia (MD = 26 µmol/l; 95% CI: -12.44 - 64.44; p = 0.18). In addition, MARS had a considerable effect in improving hepatic encephalopathy (HE) (RR = 1.54; 95% CI: 1.15-2.05; p = 0.004). However, neither MARS nor Prometheus had a mortality benefit compared to SMTRR (0.86; 95% CI: 0.71-1.03; p = 0.11 and RR = 0.87; 95% CI: 0.66-1.14; p = 0.31, respectively).

Conclusions: MARS, SPAD, and Prometheus, as liver support therapies, are equally effective in reducing albumin-bound and water-soluble substances. Moreover, MARS is associated with HE improvement. However, none of the therapies was associated with a significant reduction in mortality or adverse events.

导言:由于并非所有肝功能异常患者都适合接受移植手术,而且移植物短缺,因此肝脏支持疗法备受关注。在这方面,体外白蛋白透析装置,如单程白蛋白透析(SPAD)、普罗米修斯(Prometheus)和分子吸附剂循环系统(MARS),在补充标准医疗疗法(SMT)方面具有重要价值。目的:我们进行了一项系统性综述,总结了MARS、SPAD和Prometheus作为肝功能异常辅助治疗方法的有效性和安全性:我们在 PubMed、Medline、Cochrane Library、Web of Science 和 Google Scholar 电子数据库中广泛检索了所有用英语发表的随机试验。此外,还使用Review Manager软件进行了荟萃分析,并使用该软件中嵌入的Cochrane偏倚风险工具进行偏倚评估:共有 12 项试验符合纳入条件,其中包括 653 名患者。对这些试验的数据进行分组分析后发现,与 SMT 相比,MARS 和 Prometheus 能显著清除胆红素(MD = -5.14 mg/dl; 95% CI: -7.26 - -3.02;p < 0.00001;MD = -8.11 mg/dl; 95% CI: -12.40 - -3.82;p = 0.0002),但不能清除胆汁酸和氨。此外,MARS 在降低胆红素(MD = 2.98 mg/dl;95% CI:-4.26 - 10.22;p = 0.42 和 MD = 0.67 mg/dl;95% CI:-2.22 - 3.56;p = 0.65)、胆汁酸(MD = -17.06 µmol/l; 95% CI: -64.33 - 30.20; p = 0.48 和 MD = 16.21 µmol/l; 95% CI: -17.26 - 49.68; p = 0.34)和氨(MD = 26 µmol/l; 95% CI: -12.44 - 64.44; p = 0.18)。此外,MARS 对改善肝性脑病(HE)也有显著效果(RR = 1.54;95% CI:1.15-2.05;p = 0.004)。然而,与SMTRR相比,MARS和Prometheus均无死亡率获益(分别为0.86;95% CI:0.71-1.03;p = 0.11和RR = 0.87;95% CI:0.66-1.14;p = 0.31):结论:MARS、SPAD 和 Prometheus 作为肝脏支持疗法,在减少白蛋白结合物质和水溶性物质方面同样有效。此外,MARS 还能改善 HE。然而,没有一种疗法能显著降低死亡率或不良反应。
{"title":"Safety and efficacy of Single-Pass Albumin Dialysis (SPAD), Prometheus, and Molecular Adsorbent Recycling System (MARS) liver haemodialysis vs. Standard Medical Therapy (SMT): meta-analysis and systematic review.","authors":"Eyad Gadour, Mohammed Abdullah Kaballo, Khalid Shrwani, Zeinab Hassan, Ahmed Kotb, Ahmed Aljuraysan, Bogdan Miuţescu, Nouf Sherwani, Waleed Mahallawi","doi":"10.5114/pg.2024.139297","DOIUrl":"https://doi.org/10.5114/pg.2024.139297","url":null,"abstract":"<p><strong>Introduction: </strong>Because not all liver dysfunction patients are suitable for transplantations and there is a shortage of grafts, liver support therapies have gained interest. In this regard, extracorporeal albumin dialysis devices such as single-pass albumin dialysis (SPAD), Prometheus, and molecular adsorbent recycling system (MARS) have been valuable in supplementing standard medical therapy (SMT). However, the efficacy and safety of these devices is often questioned.Aim: We performed a systematic review to summarize the efficacy and safety of MARS, SPAD, and Prometheus as supportive treatments for liver dysfunction.</p><p><strong>Material and methods: </strong>PubMed, Medline, Cochrane Library, Web of Science, and Google Scholar electronic databases were extensively searched for all randomized trials published in English. In addition, meta-analytic analyses were performed with Review Manager software, and Cochrane's risk of bias tool embedded in this software was used for bias assessment.</p><p><strong>Results: </strong>Twelve trials including a total of 653 patients were eligible for inclusion. Subgroup analyses of data from these trials revealed that MARS and Prometheus were associated with significant removal of bilirubin (MD = -5.14 mg/dl; 95% CI: -7.26 - -3.02; <i>p</i> < 0.00001 and MD = -8.11 mg/dl; 95% CI: -12.40 - -3.82; <i>p</i> = 0.0002, respectively) but not bile acids and ammonia when compared to SMT. Furthermore, MARS was as effective as Prometheus and SPAD in the reduction of bilirubin (MD = 2.98 mg/dl; 95% CI: -4.26 - 10.22; <i>p</i> = 0.42 and MD = 0.67 mg/dl; 95% CI: -2.22 - 3.56; <i>p</i> = 0.65), bile acids (MD = -17.06 µmol/l; 95% CI: -64.33 - 30.20; <i>p</i> = 0.48 and MD = 16.21 µmol/l; 95% CI: -17.26 - 49.68; <i>p</i> = 0.34), and ammonia (MD = 26 µmol/l; 95% CI: -12.44 - 64.44; <i>p</i> = 0.18). In addition, MARS had a considerable effect in improving hepatic encephalopathy (HE) (RR = 1.54; 95% CI: 1.15-2.05; <i>p</i> = 0.004). However, neither MARS nor Prometheus had a mortality benefit compared to SMTRR (0.86; 95% CI: 0.71-1.03; <i>p</i> = 0.11 and RR = 0.87; 95% CI: 0.66-1.14; <i>p</i> = 0.31, respectively).</p><p><strong>Conclusions: </strong>MARS, SPAD, and Prometheus, as liver support therapies, are equally effective in reducing albumin-bound and water-soluble substances. Moreover, MARS is associated with HE improvement. However, none of the therapies was associated with a significant reduction in mortality or adverse events.</p>","PeriodicalId":20719,"journal":{"name":"Przegla̜d Gastroenterologiczny","volume":"19 2","pages":"101-111"},"PeriodicalIF":1.7,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11200067/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141470341","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correlation of mental and psychological status with disease activity in patients with inflammatory bowel disease using SCL-90 R Questionnaire. 使用 SCL-90 R 问卷调查炎症性肠病患者的精神和心理状况与疾病活动的相关性。
IF 1.7 Q3 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-01-01 Epub Date: 2024-05-13 DOI: 10.5114/pg.2024.139579
Ezzat Ali, Doaa Header, Khaled Abdel Aty, Nada Othman, Moamen Fawzy, Hussein El Amin, Mohamed Elnady

Introduction: Inflammatory bowel disease (IBD) can affect mental health. There is no evidence that stress is a direct cause of the disease. Most IBD patients describe an emotional impact, mainly feelings of depression and anxiety. Many questionnaires are used to assess anxiety in those patients, including SCL-90.

Aim: To investigate the correlation between mental and psychological status to disease activity in patients with inflammatory bowel disease using 90-Item Symptom Checklist (SCL-90 R) questionnaire.

Material and methods: The study included 100 patients (50 Crohn's disease (CD) patients - 50 ulcerative colitis (UC) patients). Detailed history taking, systemic physical examination, laboratory investigations, colonoscopy, and the SCL-90-R symptom checklist - a self-report psychometric instrument (questionnaire) for each patient.

Results: The mean age of Crohn's disease patients was 24.2 ±3.6 years. In ulcerative colitis the mean age was 28.5 ±7.3 years. No age or gender relation could be detected with the SCL-90 score in both groups. Our study showed a direct correlation of CD disease activity (CDAI) and endoscopic activity (SES) according to the SCL-90 R questionnaire. There was direct correlation of UC disease activity (SCCAI) and endoscopic activity (UCEIS) according to the SCL-90 R questionnaire.

Conclusions: There is a direct correlation between disease activity and endoscopic activity in UC and CD according to the SCL-90 R questionnaire.

简介炎症性肠病(IBD)会影响心理健康。没有证据表明压力是导致该病的直接原因。大多数 IBD 患者都描述了情绪上的影响,主要是抑郁和焦虑感。目的:使用 90 项症状核对表(SCL-90 R)问卷调查炎症性肠病患者的精神和心理状况与疾病活动之间的相关性:研究包括 100 名患者(50 名克罗恩病(CD)患者和 50 名溃疡性结肠炎(UC)患者)。对每位患者进行了详细的病史采集、全身体格检查、实验室检查、结肠镜检查以及自我报告心理测量工具(问卷)--SCL-90-R 症状检查表:结果:克罗恩病患者的平均年龄为(24.2 ± 3.6)岁。溃疡性结肠炎患者的平均年龄为(28.5 ± 7.3)岁。两组患者的 SCL-90 评分均与年龄或性别无关。我们的研究显示,根据 SCL-90 R 问卷,CD 疾病活动度(CDAI)与内镜活动度(SES)直接相关。根据 SCL-90 R 问卷,UC 疾病活动度(SCCAI)与内镜活动度(UCEIS)直接相关:结论:根据 SCL-90 R 问卷,UC 和 CD 的疾病活动度与内镜活动度之间存在直接相关性。
{"title":"Correlation of mental and psychological status with disease activity in patients with inflammatory bowel disease using SCL-90 R Questionnaire.","authors":"Ezzat Ali, Doaa Header, Khaled Abdel Aty, Nada Othman, Moamen Fawzy, Hussein El Amin, Mohamed Elnady","doi":"10.5114/pg.2024.139579","DOIUrl":"https://doi.org/10.5114/pg.2024.139579","url":null,"abstract":"<p><strong>Introduction: </strong>Inflammatory bowel disease (IBD) can affect mental health. There is no evidence that stress is a direct cause of the disease. Most IBD patients describe an emotional impact, mainly feelings of depression and anxiety. Many questionnaires are used to assess anxiety in those patients, including SCL-90.</p><p><strong>Aim: </strong>To investigate the correlation between mental and psychological status to disease activity in patients with inflammatory bowel disease using 90-Item Symptom Checklist (SCL-90 R) questionnaire.</p><p><strong>Material and methods: </strong>The study included 100 patients (50 Crohn's disease (CD) patients - 50 ulcerative colitis (UC) patients). Detailed history taking, systemic physical examination, laboratory investigations, colonoscopy, and the SCL-90-R symptom checklist - a self-report psychometric instrument (questionnaire) for each patient.</p><p><strong>Results: </strong>The mean age of Crohn's disease patients was 24.2 ±3.6 years. In ulcerative colitis the mean age was 28.5 ±7.3 years. No age or gender relation could be detected with the SCL-90 score in both groups. Our study showed a direct correlation of CD disease activity (CDAI) and endoscopic activity (SES) according to the SCL-90 R questionnaire. There was direct correlation of UC disease activity (SCCAI) and endoscopic activity (UCEIS) according to the SCL-90 R questionnaire.</p><p><strong>Conclusions: </strong>There is a direct correlation between disease activity and endoscopic activity in UC and CD according to the SCL-90 R questionnaire.</p>","PeriodicalId":20719,"journal":{"name":"Przegla̜d Gastroenterologiczny","volume":"19 2","pages":"165-174"},"PeriodicalIF":1.7,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11200066/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141470391","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Gastric polyps: a retrospective cohort analysis of 23,668 endoscopies indicates changing epidemiological and phenotypic characteristics. 胃息肉:对 23,668 例内窥镜检查进行的回顾性队列分析表明,其流行病学和表型特征正在发生变化。
IF 1.3 Q3 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-01-01 Epub Date: 2024-03-11 DOI: 10.5114/pg.2024.136236
Christina Kapizioni, Panagiotis Kourkoulis, Sofia Kartsoli, Georgios Koutoufaris, Panagiotis Giannelis, Aristotelis Mellos, Konstantia Milioni, George Michalopoulos, Spyridon Vrakas, Vasileios Xourgias

Introduction: Growing adoption of endoscopic procedures in clinical practice has gradually increase the detection rate of gastric polypoid lesions.

Aim: To identify the epidemiologic characteristics of gastric polyps as well as changes of these parameters during a 15-year period.

Material and methods: We reviewed all the upper endoscopies archived in our database reporting a polypoid lesion from 2003 to 2018. Demographic data, indication for endoscopy, morphological characteristics of polyps, histology, and presence of Helicobacter pylori were collected. We compared the abovementioned data between 2 periods: 2003-2010 and 2010-2018.

Results: A total of 989 (4.2%) patients from 23,668 reviewed were identified to harbour a polypoid lesion. Mean patient age was 63.2 years, with 58.8% being female. Most polyps (65.2%) were less than 5 mm in diameter and located in the fundus. Hyperplastic polyps (HPs) were the predominant type (28.6%) while fundic gland polyps (FGPs) were found in 24.1% of patients. Adenomas were the least common type (2.7%). Other pathology was identified in 43.3%. Comparison between the 2 periods revealed a rise of FGPs against HPs with a concomitant shift of location from antrum to fundus and an increase in the number of polyps per patient.

Conclusions: FGPs and HPs were the most common polyps found in our cohort, with a change of their pattern during the 15 years. It is imperative to acknowledge the distinct characteristics of gastric polyps so as to properly assess the malignant potential that some of them, or their surrounding gastric mucosa, harbour.

导言:随着内窥镜手术在临床实践中的应用越来越广泛,胃息肉病变的检出率也逐渐增加:胃息肉病变的检出率在临床实践中越来越多地采用内镜手术。目的:确定胃息肉的流行病学特征以及这些参数在15年间的变化:我们回顾了 2003 年至 2018 年期间在我们的数据库中存档的所有报告息肉病变的上消化道内镜检查。我们收集了人口统计学数据、内镜检查指征、息肉形态特征、组织学以及幽门螺杆菌的存在情况。我们比较了2003-2010年和2010-2018年两个时期的上述数据:结果:在 23,668 名受检者中,共有 989 名(4.2%)患者被确认患有息肉病变。患者平均年龄为 63.2 岁,58.8% 为女性。大多数息肉(65.2%)直径小于 5 毫米,位于眼底。增生性息肉(HPs)是主要类型(28.6%),而眼底腺息肉(FGPs)在 24.1% 的患者中发现。腺瘤是最不常见的类型(2.7%)。其他病变占 43.3%。两个时期的比较显示,FGPs 和 HPs 的比例上升,同时息肉的位置从胃窦转移到胃底,每位患者的息肉数量也有所增加:结论:FGPs 和 HPs 是我们队列中最常见的息肉,在这 15 年中,它们的形态发生了变化。必须认识到胃息肉的不同特征,以便正确评估其中一些息肉或其周围胃黏膜的恶性潜能。
{"title":"Gastric polyps: a retrospective cohort analysis of 23,668 endoscopies indicates changing epidemiological and phenotypic characteristics.","authors":"Christina Kapizioni, Panagiotis Kourkoulis, Sofia Kartsoli, Georgios Koutoufaris, Panagiotis Giannelis, Aristotelis Mellos, Konstantia Milioni, George Michalopoulos, Spyridon Vrakas, Vasileios Xourgias","doi":"10.5114/pg.2024.136236","DOIUrl":"https://doi.org/10.5114/pg.2024.136236","url":null,"abstract":"<p><strong>Introduction: </strong>Growing adoption of endoscopic procedures in clinical practice has gradually increase the detection rate of gastric polypoid lesions.</p><p><strong>Aim: </strong>To identify the epidemiologic characteristics of gastric polyps as well as changes of these parameters during a 15-year period.</p><p><strong>Material and methods: </strong>We reviewed all the upper endoscopies archived in our database reporting a polypoid lesion from 2003 to 2018. Demographic data, indication for endoscopy, morphological characteristics of polyps, histology, and presence of <i>Helicobacter pylori</i> were collected. We compared the abovementioned data between 2 periods: 2003-2010 and 2010-2018.</p><p><strong>Results: </strong>A total of 989 (4.2%) patients from 23,668 reviewed were identified to harbour a polypoid lesion. Mean patient age was 63.2 years, with 58.8% being female. Most polyps (65.2%) were less than 5 mm in diameter and located in the fundus. Hyperplastic polyps (HPs) were the predominant type (28.6%) while fundic gland polyps (FGPs) were found in 24.1% of patients. Adenomas were the least common type (2.7%). Other pathology was identified in 43.3%. Comparison between the 2 periods revealed a rise of FGPs against HPs with a concomitant shift of location from antrum to fundus and an increase in the number of polyps per patient.</p><p><strong>Conclusions: </strong>FGPs and HPs were the most common polyps found in our cohort, with a change of their pattern during the 15 years. It is imperative to acknowledge the distinct characteristics of gastric polyps so as to properly assess the malignant potential that some of them, or their surrounding gastric mucosa, harbour.</p>","PeriodicalId":20719,"journal":{"name":"Przegla̜d Gastroenterologiczny","volume":"19 1","pages":"54-59"},"PeriodicalIF":1.3,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10985756/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140870029","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Vonoprazan a novel potassium competitive acid blocker; another leap forward. 新型钾竞争性酸阻断剂 Vonoprazan;又一次飞跃。
IF 1.7 Q3 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-01-01 Epub Date: 2024-05-08 DOI: 10.5114/pg.2024.139426
Maha Elsabaawy, Ahmed Shaban, Ahmed Ezz Al-Arab, Osama Elbahr, Ahmed Edrees, Sameh Afify

Introduction: The eradication rate of Helicobacter pylori (H. pylori) has decreased due to antibiotics resistance and inadequate acid suppression. Vonoprazan is a novel potassium-competitive acid blocker (P-CAB), which has a rapid and sustained acid inhibitory effect and may be more effective than conventional proton pump inhibitors (PPIs) in H. pylori eradication.

Aim: to study the efficacy and safety of vonoprazan as a component of first-line H. pylori eradication treatment compared with conventional PPI-based therapy.

Material and methods: This randomised (one to one) non-blinded study was conducted on 400 consecutive proven H. pylori infected patients, of whom 200 received vonoprazan-based triple therapy, while 200 patients received PPI-based triple therapy for 14 days. The study outcomes were evaluated as eradication rate and adverse events in both patient groups.

Results: The eradication rate was 86% in the vonoprazan group and 74.5% in the PPI group. The vonoprazan eradication rate was significantly higher than that of PPIs (p = 0.004). There was no significant difference regarding adverse events between both patient groups.

Conclusions: Vonoprazan-based therapy was more effective than PPI-based therapy as a first-line H. pylori eradication treatment. Vonoprazan was generally safe and well tolerated.

导言:由于抗生素耐药和抑酸不足,幽门螺旋杆菌(H. pylori)的根除率有所下降。Vonoprazan是一种新型钾竞争性酸阻滞剂(P-CAB),具有快速、持续的抑酸作用,在根除幽门螺杆菌方面可能比传统质子泵抑制剂(PPI)更有效:这项随机(一对一)非盲法研究对 400 名连续确诊的幽门螺杆菌感染患者进行了研究,其中 200 名患者接受了以 vonoprazan 为基础的三联疗法,而 200 名患者接受了为期 14 天的以 PPI 为基础的三联疗法。研究结果评估了两组患者的根除率和不良反应:结果:Vonoprazan 组的根除率为 86%,PPI 组为 74.5%。Vonoprazan的根除率明显高于PPIs(P = 0.004)。两组患者的不良反应无明显差异:结论:作为根除幽门螺杆菌的一线疗法,沃诺普拉赞疗法比PPI疗法更有效。沃诺普拉赞总体上安全且耐受性良好。
{"title":"Vonoprazan a novel potassium competitive acid blocker; another leap forward.","authors":"Maha Elsabaawy, Ahmed Shaban, Ahmed Ezz Al-Arab, Osama Elbahr, Ahmed Edrees, Sameh Afify","doi":"10.5114/pg.2024.139426","DOIUrl":"https://doi.org/10.5114/pg.2024.139426","url":null,"abstract":"<p><strong>Introduction: </strong>The eradication rate of <i>Helicobacter pylori</i> (<i>H. pylori</i>) has decreased due to antibiotics resistance and inadequate acid suppression. Vonoprazan is a novel potassium-competitive acid blocker (P-CAB), which has a rapid and sustained acid inhibitory effect and may be more effective than conventional proton pump inhibitors (PPIs) in <i>H. pylori</i> eradication.</p><p><strong>Aim: </strong>to study the efficacy and safety of vonoprazan as a component of first-line <i>H. pylori</i> eradication treatment compared with conventional PPI-based therapy.</p><p><strong>Material and methods: </strong>This randomised (one to one) non-blinded study was conducted on 400 consecutive proven <i>H. pylori</i> infected patients, of whom 200 received vonoprazan-based triple therapy, while 200 patients received PPI-based triple therapy for 14 days. The study outcomes were evaluated as eradication rate and adverse events in both patient groups.</p><p><strong>Results: </strong>The eradication rate was 86% in the vonoprazan group and 74.5% in the PPI group. The vonoprazan eradication rate was significantly higher than that of PPIs (<i>p</i> = 0.004). There was no significant difference regarding adverse events between both patient groups.</p><p><strong>Conclusions: </strong>Vonoprazan-based therapy was more effective than PPI-based therapy as a first-line <i>H. pylori</i> eradication treatment. Vonoprazan was generally safe and well tolerated.</p>","PeriodicalId":20719,"journal":{"name":"Przegla̜d Gastroenterologiczny","volume":"19 2","pages":"135-142"},"PeriodicalIF":1.7,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11200074/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141470343","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The role and therapeutic effectiveness of Plantago ovata seed husk (psyllium husk) in the prevention and non-pharmacological treatment of gastrointestinal diseases. Part 1. Clinical use of psyllium husk in the treatment of irritable bowel syndrome, ulcerative colitis, and colorectal cancer. 车前子籽壳(车前子壳)在预防和非药物治疗胃肠道疾病中的作用和疗效。第 1 部分。车前子壳在治疗肠易激综合征、溃疡性结肠炎和结肠直肠癌中的临床应用。
IF 1.7 Q3 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-01-01 Epub Date: 2024-04-29 DOI: 10.5114/pg.2024.139209
Justyna Przybyszewska, Andrzej Kuźmiński, Michał Przybyszewski, Cezary Popławski

Plantago ovata is a common medicinal plant widely cultivated in tropical regions of the world. The outer seed coat of P. ovata, obtained by cleaning the seeds, contains soluble and insoluble fibre in a ratio of 7:3, making products containing P. ovata husk an ideal source of health-beneficial fibre. The results of clinical trials demonstrate the therapeutic efficacy of psyllium husk for various gastrointestinal disorders. It has also been documented that psyllium ingestion exhibits antioxidant, immunomodulatory, antiproliferative, anticancer, and antiviral effects. Such pleiotropic effects of P. ovata husk are related to the presence in its composition of arabinoxylan, which forms a gel in an aqueous environment, as well as bioactive compounds and their metabolites. This article presents the evidence available in the literature on the therapeutic potential and possible mechanisms of action of psyllium in the treatment of irritable bowel syndrome and ulcerative colitis, and prevention of colorectal cancer.

车前子是一种常见的药用植物,在世界热带地区广泛种植。通过清洗种子获得的车前子外种皮含有可溶性和不可溶性纤维,比例为 7:3,因此含有车前子壳的产品是有益健康的理想纤维来源。临床试验结果表明,洋车前子壳对各种胃肠道疾病具有疗效。此外,还有文献表明,摄入洋车前草具有抗氧化、免疫调节、抗增殖、抗癌和抗病毒作用。洋车前子壳的这些多效应与它的成分中含有阿拉伯木聚糖(在水环境中形成凝胶)以及生物活性化合物及其代谢物有关。本文介绍了有关车前子在治疗肠易激综合征和溃疡性结肠炎以及预防结直肠癌方面的治疗潜力和可能作用机制的文献证据。
{"title":"The role and therapeutic effectiveness of <i>Plantago ovata</i> seed husk (psyllium husk) in the prevention and non-pharmacological treatment of gastrointestinal diseases. Part 1. Clinical use of psyllium husk in the treatment of irritable bowel syndrome, ulcerative colitis, and colorectal cancer.","authors":"Justyna Przybyszewska, Andrzej Kuźmiński, Michał Przybyszewski, Cezary Popławski","doi":"10.5114/pg.2024.139209","DOIUrl":"https://doi.org/10.5114/pg.2024.139209","url":null,"abstract":"<p><p><i>Plantago ovata</i> is a common medicinal plant widely cultivated in tropical regions of the world. The outer seed coat of <i>P. ovata</i>, obtained by cleaning the seeds, contains soluble and insoluble fibre in a ratio of 7:3, making products containing <i>P. ovata</i> husk an ideal source of health-beneficial fibre. The results of clinical trials demonstrate the therapeutic efficacy of psyllium husk for various gastrointestinal disorders. It has also been documented that psyllium ingestion exhibits antioxidant, immunomodulatory, antiproliferative, anticancer, and antiviral effects. Such pleiotropic effects of <i>P. ovata</i> husk are related to the presence in its composition of arabinoxylan, which forms a gel in an aqueous environment, as well as bioactive compounds and their metabolites. This article presents the evidence available in the literature on the therapeutic potential and possible mechanisms of action of psyllium in the treatment of irritable bowel syndrome and ulcerative colitis, and prevention of colorectal cancer.</p>","PeriodicalId":20719,"journal":{"name":"Przegla̜d Gastroenterologiczny","volume":"19 2","pages":"121-126"},"PeriodicalIF":1.7,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11200071/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141474645","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Forgettable in the care of liver cirrhosis: the unseen culprits of progression from bad to worse. 肝硬化护理中的 "遗忘":病情恶化的隐形罪魁祸首。
IF 1.3 Q3 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-01-01 Epub Date: 2024-03-14 DOI: 10.5114/pg.2024.136361
Maha Elsabaawy, Omkosoum Alhaddad

Patients with liver cirrhosis constitute a critically ill and unique population, and their stability relies on a well-coordinated multidisciplinary team with a carefully structured plan. Overlooking any aspect of this plan can expedite disease progression, leading to severe complications. The lack of disease-specific nutritional guidance, the prevalent sedentary lifestyle among patients, and insufficient screening for hepatocellular carcinoma, oesophageal varices, sarcopaenia, minimal hepatic encephalopathy, and diabetes mellitus, along with fibrosis progression and cirrhosis decompensation, can add further complexities. Additionally, devaluing the impact of obesity in triggering liver cirrhosis can be disadvantageous. Prolonged and inappropriate use of proton pump inhibitors also poses a significant challenge with a wide range of complications. These often-unheeded aspects in the care of liver cirrhosis patients represents the unseen culprits of progression from bad to worse and warrant serious consideration.

肝硬化患者是一个病情危重的特殊群体,他们的病情稳定有赖于一个协调良好的多学科团队和一个精心制定的计划。忽视这一计划的任何方面都会加速疾病的进展,导致严重的并发症。缺乏针对特定疾病的营养指导,患者普遍存在久坐不动的生活方式,对肝细胞癌、食道静脉曲张、肌营养不良、轻度肝性脑病和糖尿病的筛查不足,以及肝纤维化进展和肝硬化失代偿,都会增加复杂性。此外,贬低肥胖对诱发肝硬化的影响也是不利的。长期不适当地使用质子泵抑制剂也是一个巨大的挑战,会引发多种并发症。在肝硬化患者的护理过程中,这些经常被忽视的方面是导致病情恶化的隐形元凶,值得认真考虑。
{"title":"Forgettable in the care of liver cirrhosis: the unseen culprits of progression from bad to worse.","authors":"Maha Elsabaawy, Omkosoum Alhaddad","doi":"10.5114/pg.2024.136361","DOIUrl":"https://doi.org/10.5114/pg.2024.136361","url":null,"abstract":"<p><p>Patients with liver cirrhosis constitute a critically ill and unique population, and their stability relies on a well-coordinated multidisciplinary team with a carefully structured plan. Overlooking any aspect of this plan can expedite disease progression, leading to severe complications. The lack of disease-specific nutritional guidance, the prevalent sedentary lifestyle among patients, and insufficient screening for hepatocellular carcinoma, oesophageal varices, sarcopaenia, minimal hepatic encephalopathy, and diabetes mellitus, along with fibrosis progression and cirrhosis decompensation, can add further complexities. Additionally, devaluing the impact of obesity in triggering liver cirrhosis can be disadvantageous. Prolonged and inappropriate use of proton pump inhibitors also poses a significant challenge with a wide range of complications. These often-unheeded aspects in the care of liver cirrhosis patients represents the unseen culprits of progression from bad to worse and warrant serious consideration.</p>","PeriodicalId":20719,"journal":{"name":"Przegla̜d Gastroenterologiczny","volume":"19 1","pages":"6-17"},"PeriodicalIF":1.3,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10985753/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140865156","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Associations of oxidative stress, metabolic disorders in colorectal cancer patients. 结直肠癌患者氧化应激与代谢紊乱的关系
IF 1.7 Q3 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-01-01 Epub Date: 2024-05-28 DOI: 10.5114/pg.2024.139995
Konrad Zaręba, Justyna Dorf, Kerianne Cummings, Seena Tabibi, Mateusz Maciejczyk, Bogusław Kędra

Introduction: Colorectal cancer have been one of the most common malignant neoplasm in the world. In most patients with this cancer, we can observe both redox homeostasis and nutritional disorders.

Aim: To assess the occurrence of oxidative stress in patients with colorectal cancer and its severity depending on the nutritional status of patients.

Material and methods: The study group consisted of 50 patients with colorectal cancer. In the control group, samples were obtained from 40 healthy subjects. Basal metabolic index and nutrition risk screening (NRS) 2002 scale was completed. The total antioxidant capacity (TAC), total oxidant status (TOS), malondialdehyde (MDA) were determined yielding the oxidative stress index (OSI) determined by the TOS/TAC ratio and TAC/MDA ratio.

Results: There were statistically significant differences (p < 0.05) in the levels of not only TAC, TOS, OSI, but also MDA and TAC/MDA. In healthy patients, the TAC and TAC/MDA level was significantly higher (p < 0.05) compared to the cancer patients, while the TOS, OSI and MDA level was significantly lower (p < 0.05). In patients with BMI < 24.9 kg/m2, the level of TAC was significantly higher and the level of TOS was significantly lower (p < 0.05) compared to patients with BMI > 24.9 kg/m2. In patients with features of malnutrition according to the NRS 2002 scale, TOS and OSI were statistically significantly higher (p < 0.05).

Conclusions: Neoplastic disease, such as colorectal cancer, precipitates an increase in oxidative stress. Concurrently, the nutritional status of patients, especially malnutrition, further intensifies this process.

简介结直肠癌是世界上最常见的恶性肿瘤之一。目的:评估结直肠癌患者氧化应激的发生情况及其严重程度与患者营养状况的关系:研究组由 50 名结直肠癌患者组成。材料和方法:研究组由 50 名结直肠癌患者组成,对照组的样本来自 40 名健康受试者。完成基础代谢指数和营养风险筛查(NRS)2002量表。测定了总抗氧化能力(TAC)、总氧化状态(TOS)和丙二醛(MDA),并根据 TOS/TAC 比值和 TAC/MDA 比值得出氧化应激指数(OSI):结果:不仅 TAC、TOS、OSI,而且 MDA 和 TAC/MDA 的水平都有明显的统计学差异(P < 0.05)。与癌症患者相比,健康患者的 TAC 和 TAC/MDA 水平明显更高(P < 0.05),而 TOS、OSI 和 MDA 水平则明显更低(P < 0.05)。与体重指数大于 24.9 kg/m2 的患者相比,体重指数小于 24.9 kg/m2 的患者的 TAC 水平明显更高,TOS 水平明显更低(p < 0.05)。根据 NRS 2002 量表,具有营养不良特征的患者的 TOS 和 OSI 在统计学上明显更高(P < 0.05):结论:结直肠癌等肿瘤性疾病会导致氧化应激增加。同时,患者的营养状况,尤其是营养不良,会进一步加剧这一过程。
{"title":"Associations of oxidative stress, metabolic disorders in colorectal cancer patients.","authors":"Konrad Zaręba, Justyna Dorf, Kerianne Cummings, Seena Tabibi, Mateusz Maciejczyk, Bogusław Kędra","doi":"10.5114/pg.2024.139995","DOIUrl":"https://doi.org/10.5114/pg.2024.139995","url":null,"abstract":"<p><strong>Introduction: </strong>Colorectal cancer have been one of the most common malignant neoplasm in the world. In most patients with this cancer, we can observe both redox homeostasis and nutritional disorders.</p><p><strong>Aim: </strong>To assess the occurrence of oxidative stress in patients with colorectal cancer and its severity depending on the nutritional status of patients.</p><p><strong>Material and methods: </strong>The study group consisted of 50 patients with colorectal cancer. In the control group, samples were obtained from 40 healthy subjects. Basal metabolic index and nutrition risk screening (NRS) 2002 scale was completed. The total antioxidant capacity (TAC), total oxidant status (TOS), malondialdehyde (MDA) were determined yielding the oxidative stress index (OSI) determined by the TOS/TAC ratio and TAC/MDA ratio.</p><p><strong>Results: </strong>There were statistically significant differences (<i>p</i> < 0.05) in the levels of not only TAC, TOS, OSI, but also MDA and TAC/MDA. In healthy patients, the TAC and TAC/MDA level was significantly higher (<i>p</i> < 0.05) compared to the cancer patients, while the TOS, OSI and MDA level was significantly lower (<i>p</i> < 0.05). In patients with BMI < 24.9 kg/m<sup>2</sup>, the level of TAC was significantly higher and the level of TOS was significantly lower (<i>p</i> < 0.05) compared to patients with BMI > 24.9 kg/m<sup>2</sup>. In patients with features of malnutrition according to the NRS 2002 scale, TOS and OSI were statistically significantly higher (<i>p</i> < 0.05).</p><p><strong>Conclusions: </strong>Neoplastic disease, such as colorectal cancer, precipitates an increase in oxidative stress. Concurrently, the nutritional status of patients, especially malnutrition, further intensifies this process.</p>","PeriodicalId":20719,"journal":{"name":"Przegla̜d Gastroenterologiczny","volume":"19 2","pages":"206-213"},"PeriodicalIF":1.7,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11200079/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141470389","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clostridioides difficile infection: a changing treatment paradigm. 艰难梭菌感染:不断变化的治疗模式。
IF 1.3 Q3 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-01-01 Epub Date: 2024-03-11 DOI: 10.5114/pg.2024.136237
Yousif Al Naser, Marriam AlGashami, Layth Aljashaami

Clostridioides difficile infection (CDI) poses a persistent challenge in healthcare, with substantial morbidity and mortality implications. This comprehensive review explores current CDI management, emphasising guidelines from IDSA, SHEA, and ESCMID. Additionally, this study spotlights recent drug developments that have the potential to reshape CDI treatment paradigms. Within the current treatment landscape, fidaxomicin, vancomycin, bezlotoxumab, and faecal microbiota transplantation offer varied options, each with its unique strengths and limitations. Fidaxomicin, effective yet resource-constrained, presents a dilemma, with vancomycin emerging as a pragmatic alternative. Bezlotoxumab, though augmenting antibiotics, grapples with cost and safety concerns. Meanwhile, faecal microbiota transplantation, highly efficacious, confronts evolving safety considerations. The horizon of CDI treatment also features promising therapies such as SER-109 and Rebyota, epitomising the evolving paradigm. As CDI management advances, the critical role of standardised microbiome restoration therapies becomes evident, ensuring long-term safety and diversifying treatment strategies.

艰难梭菌感染(CDI)是医疗保健领域的一项长期挑战,对发病率和死亡率都有重大影响。本综述探讨了当前的 CDI 管理方法,重点介绍了 IDSA、SHEA 和 ESCMID 的指南。此外,本研究还重点介绍了近期有可能重塑 CDI 治疗模式的药物开发。在目前的治疗格局中,非达霉素、万古霉素、贝曲妥珠单抗和粪便微生物群移植提供了多种选择,每种药物都有其独特的优势和局限性。非达霉素疗效显著,但资源有限,因此成为一种两难选择,而万古霉素则成为一种实用的替代疗法。Bezlotoxumab 虽然能增强抗生素的疗效,但也面临成本和安全问题。同时,粪便微生物群移植虽然疗效显著,但也面临着不断变化的安全性问题。在 CDI 治疗领域,SER-109 和 Rebyota 等疗法也大有可为,成为不断发展的范例的缩影。随着 CDI 治疗的发展,标准化微生物组恢复疗法的关键作用变得显而易见,它能确保长期安全性并使治疗策略多样化。
{"title":"<i>Clostridioides difficile</i> infection: a changing treatment paradigm.","authors":"Yousif Al Naser, Marriam AlGashami, Layth Aljashaami","doi":"10.5114/pg.2024.136237","DOIUrl":"https://doi.org/10.5114/pg.2024.136237","url":null,"abstract":"<p><p><i>Clostridioides difficile</i> infection (CDI) poses a persistent challenge in healthcare, with substantial morbidity and mortality implications. This comprehensive review explores current CDI management, emphasising guidelines from IDSA, SHEA, and ESCMID. Additionally, this study spotlights recent drug developments that have the potential to reshape CDI treatment paradigms. Within the current treatment landscape, fidaxomicin, vancomycin, bezlotoxumab, and faecal microbiota transplantation offer varied options, each with its unique strengths and limitations. Fidaxomicin, effective yet resource-constrained, presents a dilemma, with vancomycin emerging as a pragmatic alternative. Bezlotoxumab, though augmenting antibiotics, grapples with cost and safety concerns. Meanwhile, faecal microbiota transplantation, highly efficacious, confronts evolving safety considerations. The horizon of CDI treatment also features promising therapies such as SER-109 and Rebyota, epitomising the evolving paradigm. As CDI management advances, the critical role of standardised microbiome restoration therapies becomes evident, ensuring long-term safety and diversifying treatment strategies.</p>","PeriodicalId":20719,"journal":{"name":"Przegla̜d Gastroenterologiczny","volume":"19 1","pages":"1-5"},"PeriodicalIF":1.3,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10985755/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140863772","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Functional gastrointestinal disorders in Jordanian infants: a pilot study. 约旦婴儿的功能性胃肠功能紊乱:一项试点研究。
IF 1.3 Q3 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-01-01 Epub Date: 2023-02-03 DOI: 10.5114/pg.2023.124757
Yazan O Al Zu'bi, Eyad Altamimi, Ahmed H Al Sharie, Dawood Yusef, Wasim Khasawneh

Introduction: Functional gastrointestinal disorders (FGIDs) encompass a wide spectrum of disorders that may be diagnosed using the Rome criteria.

Aim: To identify the prevalence and risk factors for the development of FGIDs in Jordanian infants.

Material and methods: We conducted a cross-sectional study to investigate the prevalence of FGIDs among infants and characterise any possible risk factors. Between 1 January 2020, and 30 December 2020, patients who presented to the paediatric follow-up clinic at King Abdullah University Hospital were recruited. Parents were interviewed and asked to complete an Arabic version of the Rome IV diagnostic questionnaire for pediatric gastrointestinal disorders for neonates and toddlers. Data regarding the parents' gastrointestinal symptoms and children's medical history were collected. Children's electronic medical files were also reviewed.

Results: The study included 127 children, 78 (61%) were males. The median age was 40 days. According to the Rome IV criteria eighty-two (64%) of the infants fit the diagnosis for at least one disorder. The most prevalent disorder was functional constipation (n = 78, 95%) followed by infant dyschezia (n = 11, 13%). Compared to infants who did not meet the diagnostic criteria, herb intake and circumcision rates were significantly higher among those who did. Univariate analyses revealed that Infants with FGIDs were more likely to ingest herbs.

Conclusions: FGIDs were common among young infants. Functional constipation was the most commonly diagnosed FGID. Infants with with FGIDs were more likely to intake herbs to ease the symtpoms.

导言:功能性胃肠病(FGIDs)包括多种疾病,可根据罗马标准进行诊断。目的:确定约旦婴儿中功能性胃肠病的发病率和风险因素:我们进行了一项横断面研究,以调查 FGIDs 在婴儿中的患病率,并确定任何可能的风险因素。研究招募了 2020 年 1 月 1 日至 2020 年 12 月 30 日期间到阿卜杜拉国王大学医院儿科复诊的患者。他们与家长进行了面谈,并要求家长填写阿拉伯语版的新生儿和幼儿小儿胃肠道疾病罗马IV诊断问卷。此外,还收集了有关家长胃肠道症状和儿童病史的数据。此外,还查阅了儿童的电子病历:研究共包括 127 名儿童,其中 78 名(61%)为男性。年龄中位数为 40 天。根据罗马IV标准,82名婴儿(64%)至少有一种疾病符合诊断标准。最常见的疾病是功能性便秘(78 例,占 95%),其次是婴儿排便障碍(11 例,占 13%)。与不符合诊断标准的婴儿相比,符合诊断标准的婴儿的草药摄入量和包皮环切率明显较高。单变量分析显示,患有FGID的婴儿更有可能摄入草药:结论:FGID 在幼儿中很常见。结论:功能性便秘是婴幼儿中最常见的疾病。患有功能性便秘的婴儿更有可能摄入草药来缓解症状。
{"title":"Functional gastrointestinal disorders in Jordanian infants: a pilot study.","authors":"Yazan O Al Zu'bi, Eyad Altamimi, Ahmed H Al Sharie, Dawood Yusef, Wasim Khasawneh","doi":"10.5114/pg.2023.124757","DOIUrl":"10.5114/pg.2023.124757","url":null,"abstract":"<p><strong>Introduction: </strong>Functional gastrointestinal disorders (FGIDs) encompass a wide spectrum of disorders that may be diagnosed using the Rome criteria.</p><p><strong>Aim: </strong>To identify the prevalence and risk factors for the development of FGIDs in Jordanian infants.</p><p><strong>Material and methods: </strong>We conducted a cross-sectional study to investigate the prevalence of FGIDs among infants and characterise any possible risk factors. Between 1 January 2020, and 30 December 2020, patients who presented to the paediatric follow-up clinic at King Abdullah University Hospital were recruited. Parents were interviewed and asked to complete an Arabic version of the Rome IV diagnostic questionnaire for pediatric gastrointestinal disorders for neonates and toddlers. Data regarding the parents' gastrointestinal symptoms and children's medical history were collected. Children's electronic medical files were also reviewed.</p><p><strong>Results: </strong>The study included 127 children, 78 (61%) were males. The median age was 40 days. According to the Rome IV criteria eighty-two (64%) of the infants fit the diagnosis for at least one disorder. The most prevalent disorder was functional constipation (<i>n</i> = 78, 95%) followed by infant dyschezia (<i>n</i> = 11, 13%). Compared to infants who did not meet the diagnostic criteria, herb intake and circumcision rates were significantly higher among those who did. Univariate analyses revealed that Infants with FGIDs were more likely to ingest herbs.</p><p><strong>Conclusions: </strong>FGIDs were common among young infants. Functional constipation was the most commonly diagnosed FGID. Infants with with FGIDs were more likely to intake herbs to ease the symtpoms.</p>","PeriodicalId":20719,"journal":{"name":"Przegla̜d Gastroenterologiczny","volume":"1 1","pages":"67-73"},"PeriodicalIF":1.3,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10985758/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70474818","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Przegla̜d Gastroenterologiczny
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1